视网膜专科医生行抗血管内皮生长因子注射治疗的新生血管性青光眼眼中需手术或失明的危险因素
这项回顾性队列研究纳入2011年9月8日至2020年5月8日在一家大型视网膜亚专科诊所因新生血管性青光眼(NVG)接受玻璃体腔抗血管内皮生长因子注射治疗的301只新发眼,分析基线特征与需青光眼手术或失明的关联。结果显示31%需青光眼手术、20%进展至无光感,眼压>35 mmHg、使用两种及以上局部降眼压药、视力差于20/100、增殖性糖尿病视网膜病变、眼痛或不适及新患者身份与更高风险相关,作者认为应强烈考虑及时转诊青光眼专科。
要点
- 301只新发NVG眼中,31%需青光眼手术,20%进展至无光感。
- 基线眼压>35 mmHg、视力差于20/100、增殖性糖尿病视网膜病变等与更高风险相关。
- 作者认为应强烈考虑将高风险患者及时转诊至青光眼专科。
核心结论
- 就诊于视网膜专科医生时具有若干基线特征的NVG眼,尽管使用抗血管内皮生长因子治疗,似乎仍预示更高的青光眼失控风险。
- 作者认为应强烈考虑将这些患者及时转诊至青光眼专科。
研究设计与样本
- 这是一项回顾性队列研究,纳入2011年9月8日至2020年5月8日在一家大型视网膜亚专科诊所就诊、既往未接受青光眼手术、诊断时接受玻璃体腔抗血管内皮生长因子注射治疗的NVG患者。
- 共纳入301只新发NVG眼。
主要发现
- 301只新发NVG眼中,31%需青光眼手术,20%进展至无光感。
- 诊断NVG时眼压>35 mmHg(P < 0.001)与更高青光眼手术或失明风险相关。
- 诊断NVG时使用两种及以上局部降眼压药(P = 0.003)与更高青光眼手术或失明风险相关。
- 诊断NVG时视力差于20/100(P = 0.024)、增殖性糖尿病视网膜病变(P = 0.001)、眼痛或不适(P = 0.010)及新患者身份(P = 0.015)与更高青光眼手术或失明风险相关。
- 在无屈光介质混浊患者的亚组分析中,全视网膜光凝的效果未达统计学显著(P = 0.199)。
临床怎么用
- 作者认为,对就诊时具有上述基线特征的新生血管性青光眼患者,应强烈考虑及时转诊至青光眼专科。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine baseline patient characteristics that predict the need for glaucoma surgery or blindness in eyes with neovascular glaucoma (NVG) despite intravitreal antivascular endothelial growth factor therapy. METHODS: This is a retrospective cohort study of patients with NVG who had not previously received glaucoma surgery and were treated with intravitreal antivascular endothelial growth factor injections at the time of diagnosis, from September 8, 2011, to May 8, 2020, at a large, retina subspecialty practice. RESULTS: Of 301 newly presenting NVG eyes, 31% required glaucoma surgery and 20% progressed to no light perception vision despite treatment. Patients with intraocular pressure >35 mmHg ( P < 0.001), two or more topical glaucoma medications ( P = 0.003), worse than 20/100 vision ( P = 0.024), proliferative diabetic retinopathy ( P = 0.001), eye pain or discomfort ( P = 0.010), and new patient status ( P = 0.015) at the time of NVG diagnosis were at a higher risk of glaucoma surgery or blindness regardless of antivascular endothelial growth factor therapy. The effect of panretinal photocoagulation was not statistically significant in a subgroup analysis of patients without media opacity ( P = 0.199). CONCLUSION: Several baseline characteristics at the time of presentation to a retina specialist with NVG seem to portend a higher risk of uncontrolled glaucoma despite the use of antivascular endothelial growth factor therapy. Prompt referral of these patients to a glaucoma specialist should be strongly considered.
引用
- Massenzio E, Xu D, Abishek R, et al. RISK FACTORS FOR SURGERY OR BLINDNESS IN NEOVASCULAR GLAUCOMA EYES TREATED WITH ANTI-VEGF INJECTIONS BY A RETINA SPECIALIST. Retina. 2023. PMID: 36913629. doi:10.1097/IAE.0000000000003780
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。